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SHORT COMMUNICATION
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ABSTRACT
Inhibitors of serine proteases are not only extremely useful in the basic research but are also
applied extensively in clinical settings. Using Systematic Evolution of Ligands by Exponential
Enrichment (SELEX) approach we developed a family of novel, single-stranded DNA aptamers
capable of specific trypsin inhibition. Our most potent candidate (T24) and its short version (T59)
were thoroughly characterised in terms of efficacy. T24 and T59 efficiently inhibited bovine tryp-
sin with Ki of 176nM and 475nM, respectively. Interestingly, in contrast to the majority of known
trypsin inhibitors, the selected aptamers have superior specificity and did not interact with por-
cine trypsin or any human proteases tested. These included plasmin and thrombin characterised
by trypsin-like substrate specificity. Our results demonstrate that SELEX may be successfully
employed in the development of potent and specific DNA based protease inhibitors.
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Introduction
The design and development of small molecule inhibitors of
proteases have proved an extremely daunting task due to selectiv-
ity problems. Trypsin has been extensively characterised as a type
serine protease and a convenient model to investigate enzyme
inhibition. Multiple inhibitors have been identified and their bind-
ing was thoroughly characterised. A large number of small mol-
ecule inhibitors have been developed which bind at the substrate
binding cleft mimicking interactions of the substrate while in a
majority of cases irreversibly modify the catalytic residues. Most of
those inhibitors suffer from selectivity issues. A number of protein
and peptide inhibitors have also been identified. These also bind
at the active site preventing substrate access but avoid hydrolysis.
While certain protein inhibitors are highly selective, in a majority
of cases they are less suitable for medical applications. Only a
very small number of exosite protease inhibitors have been
described1,2.
Lack of specificity when targeting catalytic site is a recurrent
topic and major challenge leading to the lack of specificity and
potential life-threatening toxic effects. An interesting alternative is
provided by oligonucleotide aptamers – molecules with single-
stranded DNA or RNA scaffold, that bind target proteins with
unique selectivity and high affinity, largely alleviating a significant
number of problems associated small molecule inhibitors. Thanks
to their exceptional properties (e.g. straightforward chemical
modification, lack of toxicity, the possibility of in vitro synthesis),
aptamers constitute an excellent tool for both, basic research and
development of therapeutic strategies (e.g. target validation,
imaging, etc.). Most importantly, aptamers have great potential for
clinical use.
Several RNA aptamers capable of inhibiting proteolytic activity
have been reported3–7. In this study, we describe the develop-
ment and characterisation of a nano-molar single-stranded DNA
aptameric inhibitor of bovine trypsin characterised by exceptional
selectivity.
Methods
All reagents and proteins, if not mentioned otherwise, were pur-
chased from Sigma-Aldrich (Darmstadt, Germany).
In vitro selection
Single-stranded DNA library (N50), composed of 50 nucleotides
random region flanked by fixed primer binding sequences: 50-
CATGCTTCCCCAGGGAGATG-N50-GAGGAACATGCGTCGCAAAC-30,
was synthesised at 0.2lM scale and HPLC purified (IBA, Germany).
The N50 library was selected against Mag-Trypsin, commercially
available bovine trypsin immobilised on magnetic beads (Clontech
Laboratories, Inc. CA, USA) using SELEX protocol8 with modifica-
tions. Briefly, 0.3ml of beads (3 ll in the initial cycle) were mixed
with denatured (5min at 92 C) ssDNA pool from previous cycle of
selection (N50 library in the initial cycle). After 30min incubation
at room temperature (RT) with gentle agitation, the beads were
washed three times with selection buffer: PBS (phosphate-buffered
saline pH 7.4) supplemented with 5mM MgCl2, 10mM KCl and
0.01% Tween20. Magnetic particle concentrator rack was used for
washing. Beads were re-suspended in dH2O, the enriched ssDNA
pool was recovered under denaturing conditions (92 C for 5min)
and amplified in PCR. 400ll of PCR mix containing 1lM primers
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(unmodified ss50_For: 50-CATGCTTCCCCAGGGAGATG-30 and 5’-
phosphorylated ss50_Rev: 50-GTTTGCGACGCATGTTCCTC-30),
0.5mM dNTPs, 2.5mM MgCl2, 1.25U/100 ll of Taq polymerase
(Thermo Scientific) was prepared and mixed with 3–0.3ll of beads
with immobilised protein and bound aptamers. The PCR was per-
formed for 30 cycles, consisting of denaturation at 95 C for 2min,
annealing at 53 C for 30 s, and extension at 72 C for 30 s fol-
lowed by final extension at 72 C for 5min. PCR products were
extracted with phenol-chloroform-isoamyl alcohol mixture (Sigma-
Aldrich, Germany) and precipitated with isopropanol overnight at
20 C. After centrifugation, DNA pellets were washed twice with
70% ethanol, dried, dissolved in 100ll of dH2O and subjected to
k exonuclease (ThermoScientific) digestion of phosphorylated
strand to retrieve the unmodified strand (single-stranded DNA
pool). Digestion was performed for 1.5 h at 37 C, with gentle
shaking, in 500 ll mixture containing 100U of k exonuclease.
Digestion products (ssDNA) were extracted with phenol-chloro-
form-isoamyl alcohol mixture, precipitated and dissolved in 100ll
of dH2O, ssDNA samples were stored at 20 C before next selec-
tion cycle. In order to eliminate non-specific binding of oligonu-
cleotides, yeast tRNA (Invitrogen) and BSA (Bioshop, Canada) were
added as competitors during incubation of ssDNA pool with
immobilised trypsin (negative selection against empty beads was
not conducted).
After ten initial selection cycles, unspecific PCR products
became persistent. To remove unwanted products samples were
electrophoresed in 10% polyacrylamide gels with 7M urea in 0.5
TBE buffer for 90min at 90 V at 4 C. The band corresponding to
90 nucleotide long fragments were cut, repeatedly frozen and
thawed for water extraction. Purified fragments were PCR ampli-
fied. DNA was extracted from with phenol-chloroform-isoamyl
alcohol mixture and precipitated with isopropanol and then sub-
jected to k exonuclease digestion as described above. After 15th
round of selection, the aptamers were cloned into a plasmid,
amplified and sequenced (see Supplementary material – Cloning
and sequencing). Analysis of obtained sequences was performed
with T-Coffee (multiple sequence alignment) programme.
ELISA binding assay
Binding of selected aptamers to bovine trypsin was evaluated by
ELISA. 96-well microtiter plate (Nunc, Rochester, NY, USA) was
coated with 100 ll of bovine trypsin (10mg/ml in PBS) for 1 h at
RT. All further steps were performed at RT. Unbound trypsin was
removed by washing with PBS-T (PBS with 0.05% Tween20). Non-
specific binding sites were blocked with 1% BSA in PBS-T for 1 h.
Excess of BSA was removed by washing. Serial dilutions of biotiny-
lated aptamers ranging from 0 to 4 mM in selection buffer (100ll)
were added to the wells and incubated for 1 h. To determine non-
specific binding, control sequence (50-biotin-CGTACGGTCGACGCT
AGC-(ACTG)12A-CACGTGGAGCTCGGATCC-30) was used. Unbound
biotin-labeled aptamers were removed by extensive washing with
selection buffer. 100ll of horse-radish-peroxidase HRP-conjugated
streptavidin (1:200 dilution; R&D Systems) was added to the wells.
After 20min incubation, unbound HRP-conjugated streptavidin
was removed by washing and 100 ml of HRP reagent substrate
(R&D Systems, MN, USA) was added. After 5–10min, when a
clearly visible blue colour developed, the reaction was stopped by
the addition of 50ll of 1M H2SO4. The absorbance at 450 nm and
540 nm (correction for optical imperfections of the plates) was
determined using a PowerWaveXmicroplate reader (BioTek).
Immobilisation tests
To confirm the ability of selected aptamers to bind trypsin, immo-
bilisation assay was used. 5’-biotin-labeled, HPLC purified ssDNA
aptamers (4 lM; IBA, Germany) were incubated in selection buffer
at RT for 30min with 50ll of Streptavidin M-280 Dynabeads
(Invitrogen). The beads were washed three times with selection
buffer in order to remove unbound aptamers and then incubated
in selection buffer with bovine trypsin (16 lM in a total volume of
50 ll) for 20min at RT with gentle agitation. The excess of trypsin
was removed by washing with selection buffer. The beads were
re-suspended in 20ll SDS-PAGE loading buffer. The proteins were
denatured (95 C for 5min) and resolved in 10% SDS-polyacryl-
amide gel. The gels were stained with Coomassie Brilliant Blue
R-250.
Binding kinetics analysis
The affinity of T24 aptamer for bovine trypsin was determined
using Surface Plasmon Resonance (for details see Supplementary
material – methods).
Aptamer shortening
The sequence of the best-selected aptamer, T24, was divided into
10 nt long segments and nine mutational variants lacking one of
these segments were obtained by chemical synthesis (Figure 3).
Each aptamer mutant was analysed for its ability to inhibit bovine
trypsin to determine regions within the aptamer sequence respon-
sible for trypsin inhibition.
Trypsin inhibition assay
Aptamers (0–10mM) were incubated with trypsin (0.5mM) and
residual activity of the enzyme was determined using synthetic
chromogenic substrate Na-Benzoyl-L-arginine 4-nitroanilide hydro-
chloride (BAPNA). Activity was determined in the trypsin aptamer
assay buffer (TAAB): 0.1M Tris, 150mM NaCl, 5mM CaCl2, 10mM
KCl, 5mM MgCl2, 0.02% Tween 20, pH 7.5 (for details see
Supplementary material – methods).
Determination of the inhibition mode and Ki
Trypsin was active site titrated with 4-nitrophenyl 4-guanidinoben-
zoate9. Steady-state inhibition constant (Ki) was determined as
described previously10 employing model for mixed inhibition (for
details see Supplementary material – methods).
Screening of aptamer specificity
Bovine and porcine trypsin (200 nM), human plasmin (40 nM),
human thrombin (20 nM), human neutrophil elastase (20 nM),
human cathepsin G (40 nM), and porcine pancreatic elastase
(20 nM) were preincubated with 50 molar excess of T24 and T59
aptamers in TAAB for 30min at 37 C. Relevant substrates were
added: MeoSuc-AAPV-pNA (500 lM) for elastases, Suc-AAPF-pNA
(500 lM) for cathepsin G, BAPNA (1.5mM) for trypsins, Boc-QAR-
AMC (100 lM) for thrombin and plasmin. Residual activity was
monitored for 30min at 37 C using a SpectraMAX microplate
reader (Molecular Devices, Sunnyvale, CA) for pNA substrates
(absorbance at 410 nm) and SpectraMax Gmini XS
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(MolecularDevices) for Boc-Val-Pro-Arg-AMC (excitation: 380 nm,
emission: 460 nm).
Results
Aptamer selection
Aptamers with affinity to bovine trypsin were selected from a ran-
dom pool using SELEX methodology. After 15th round of selec-
tion, the pool was cloned into a plasmid and sequenced.
Homologies were analysed among obtained sequences to identify
six prevalent aptamer families: T3, T6, T21, T22, T24, and T35
(Table 1).
Analysis of binding capacity of selected aptamers
The binding capacity of identified families towards bovine trypsin
was analysed by ELISA. Our results showed that aptamers anno-
tated as T21, T22, and T24 were characterised by highest and
almost identical properties. T3 have only around 50% of the bind-
ing capacity of the previous three aptamers. Both T6 and T35
showed very low binding on the level of a non-specific sequence
serving as a negative control (NC) (Figure 1(A)).
The results of the ELISA assay were verified in an alternative
test where the interaction of trypsin with biotinylated aptamers
immobilised on streptavidin conjugated to magnetic beads was
tested. In line with previous results, T21, T22, and T24 were most
efficient in retaining trypsin (Figure 1(B)), with T3 aptamer show-
ing significantly weaker band intensity corresponding directly
lower to trypsin affinity. Aptamers T6 and T35 did not show any
visible binding remaining on the level of negative control.
Trypsin inhibition
Although our previous experiments showed efficient binding of
T21, T22, T24, and T3 to bovine trypsin, that might not directly
correlate with enzyme inhibition. In order to verify the ability of
the selected aptamers not only to bind but also to inhibit trypsin,
residual activity of the enzyme was determined after pre-incuba-
tion with aptamers of interest (Figure 2). We found that the inhibi-
tory efficacy of tested aptamers correlated closely with their
binding capacity. T21, T22, T24, and T3 were the most efficient
inhibitors whereas T6 and T35 were significantly less effective in
our assay. Of note, although T6 and T35 have demonstrated in
the previous experiments very weak interaction with the target
molecule (on the level of negative control) they still provided sig-
nificant inhibition of the target enzyme. This could be explained
by the limitations of the binding assay that is not able to detect
very weak interactions (compounds characterised by high Kd).
These aptamers were however not considered further due to poor
inhibition. Of comparably behaving T21, T22 and T24, the latter
was chosen for further analysis. The affinity of T24 aptamer
towards trypsin has been characterised using Surface Plasmon
Resonance demonstrating kon=1.03 106 M1s1, koff=3.15 103
s1, and the Kd of = 3.06 109 M (Supplementary Figure 2).
Shortening of T24 aptamer
Primary aptamers identified using the SELEX approach originated
from the relatively long initial library. In general, not all nucleic
acids of the aptamers are necessary for the binding affinity
between the aptamers and the targets. To determine the minimal
sequence of T24 aptamer necessary for binding and inhibition of
trypsin, the T24 was divided into 10 nucleotide long segments, to
narrow down the sequence region responsible for the target bind-
ing (Figure 3). Segments (a, b, h and i) originated from the con-
served flanking sequence of the library (primer attachment sites)
while segments (c–g) encompassed the variable region of the
library. All variants were obtained where each particular segment
was missing and their inhibitory activity towards trypsin was
screened. Removal of any of the segments (b–d, f–h) resulted in
complete loss of inhibition demonstrating the importance of these
Table 1. Aptamers sequences.
Designation Sequences
T3 CATGCTTCCCCAGGGAGATGACGCACATGTGGTTTTTAGACGGGCGTCCTGTGATGGGAGCGGGGTTAGGGAGGAACATGCGTCGCAAAC
T6 CATGCTTCCCCAGGGAGATGTCGGCGGGATATCGTGGCGGTTTGTTGGAGTTAGGGCATCTTCGGACTGGGAGGAACATGCGTCGCAAAC
T21 CATGCTTCCCCAGGGAGATGGGTGTGGGGTTAGGTCACTTTATGGTTGGTTCCATTGTGTCAGGGAGCCGGGAGGAACATGCGTCGCAAAC
T22 CATGCTTCCCCAGGGAGATGGGTGTGAGGTTAGGAAATCTGTGTTGAACACTGCTTTCAGGGGGCTTGGGAGGAACATGCGTCGCAAAC
T24 CATGCTTCCCCAGGGAGATGGGTGTGAGGTTAGTTTGCGGGAACTAGAATTCCTGGCAAAGGGGGGCCTGGAGGAACATGCGTCGCAAAC
T35 CATGCTTCCCCAGGGAGATGTGGCATAACCATCTCCGATAATATGGGTCACAGCTGGGCGGAAGGAGCTCGAGGAACATGCGTCGCAAAC
T59 CATGCTTCCCCAGGGAGATGGGTGTGAGGTTAGTTTGCGGTCCTGGCAAAGGGGGGCCTGGAGGAACATG
T159 CAGGGAGATGGGTGTGAGGTTAGTTTGCGGTCCTGGCAAAGGGGGGCCTGGAGGAACATG
Figure 1. Interaction of aptamers with bovine trypsin. (A). ELISA. Biotinylated
aptamers at indicated concentrations were incubated with immobilised trypsin
and detected with HRP-streptavidin. NC - negative control. (B) Biotinylated
aptamers were immobilised on magnetic beads. Beads were contacted with
bovine trypsin and retained fraction was analyzed by SDS-PAGE after thor-
ough washing.
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regions for trypsin interaction or aptamer structure. Conversely,
removal of segments a, e or i had no effect on inhibition demon-
strating that these regions of T24 aptamer are not involved either
in inhibition or aptamer structure stabilisation (Figure 3).
Based on the above findings two shortened versions of T24,
namely T59 (segments e and i removed) and T159 (segments a, e
and i removed) were obtained (Table 1 and Figure 3(C)) and
further characterised. Interestingly, T59 preserved the inhibitory
capacity of parent aptamer T24 while T159 lost the inactivity
(Figure 4).
Determination of inhibition constant
To further compare the inhibitory potency of T24 and T59 and
potentially determine the mode of inhibition kinetic analysis of
inhibition was performed. The inhibition curve followed the
Michaelis–Menten kinetics and was dependent on both substrate
and aptamer concentration (Supplementary Figure 1).
Extrapolations of the simple linear regression model fitted to the
experimental points crossed away from any of the axes on
Lineweaver–Burk plot (Supplementary Figure 1). This data clearly
shows that the inhibition of trypsin by tested aptamers is revers-
ible and best described by a mixed-model of enzyme inhibition.
The steady-state inhibition constant (Ki) was determined as a par-
ameter most suitable for describing the potency of reversible
inhibitors. T24 and T59 inhibited trypsin with Ki of 176± 16 and
475 ± 48 nM, respectively.
Figure 2. Inhibition of trypsin by aptamers. Aptamers at indicated concentrations
were pre-incubated with bovine trypsin. Residual trypsin activity was determined
using chromogenic substrate (L-BAPNA) by monitoring absorbance at 405 nm.
Figure 3. Identification of minimal sequence responsible for inhibitory capacity of T24. (A) Schematic representation of probing scheme – nine new aptamers were
obtained each devoid of depicted region. Each region (a–i) represents 10 nucleotides. Primer interaction sites are shaded grey. (B) The inhibitory activity of aptamers
depicted in panel A against bovine trypsin. Enzyme was pre-incubated with tested aptamer and residual activity was determined using L-BAPNA. (C) Schematic repre-
sentation of two resulting versions of shortened T24 aptamer.
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Analysis of inhibition specificity
To determine the specificity of interaction between the T24 and
T59 aptamers and the target enzyme inhibition of a closely related
porcine trypsin as well as commercially available mammalian pro-
teases were tested. Presence of T24 or T59 had no impact on the
activity of porcine pancreatic elastase, human cathepsin G, neutro-
phil elastase, plasmin and thrombin (Figure 5 and Figure 6) dem-
onstrating that both our candidates are not only efficient but also
highly selective. Such high specificity is a unique feature of
aptamers as compared to small molecule inhibitors and also
greater than that of many protein/peptide inhibitors.
Discussion
Trypsin is not only a model enzyme in investigations of proteolysis
but also a highly relevant clinical target. A large number of natural
protein/peptide inhibitors and small molecule inhibitors of trypsin
have been reported, with the former being usually characterised
by better specificity.
A popular low molecular weight inhibitor nafamostat mesilate
(FUT-175), a synthetic serine protease inhibitor often used in basic
medical research, inhibits trypsin with Ki of 15 nM but presents
low specificity inhibiting a number of proteases pivotal in coagula-
tion cascade11. Gabexate mesylate, another synthetic protease
inhibitor, shown to be effective in treating patients with sepsis-
associated disseminated intravascular coagulation, also exhibits
significant cross-reactivity inhibiting human tryptase (Ki¼ 3.4 nM),
bovine tryptase (180 nM) and trypsin (2 lM)12. Developed by us
aptamers T24 and T59 inhibited trypsin with Kis of 176 and
475 nM, respectively. Affinity values of our aptamers, however,
higher than the synthetic inhibitors described above have an
undisputed advantage of high specificity. Neither T24 nor T59 had
any effect on tested elastases, cathepsin G, plasmin and thrombin.
Not even the activity of porcine trypsin was affected. That level of
specificity ensures selectivity even at higher concentrations com-
pensating lower affinity and potentially eliminating undesired side
effects. That level of specificity is comparable with protein inhibi-
tors13, which unlike aptamers are highly complex in production,
expensive and hard to scale up. Small molecules are usually more
promiscuous as compared to aptamers or proteins/peptides. For
example, gabexate despite targeted at human tryptase
(Ki¼ 3.4 nM), also inhibits thrombin (500 nM), plasmin (1.5 lM), fac-
tor Xa (2 lM) and trypsin (2 lM). Nafamostat inhibits not only tryp-
sin (Ki¼ 15 nM), but also thrombin (84 nM), C1r (14 nM), C1s
(38 nM), tryptase (95 pM), plasmin and kallikrein11. Broad specificity
is a common problem limiting the use of small molecules not
only in clinical setting but also in the laboratory.
Low specificity of small-molecule inhibitors is directly related to
their mechanism of action. They interact directly with amino acids
within the catalytic cleft of target enzymes, which are usually not
specific for particular protease, but rather the entire protease fam-
ily characterised by a similar mechanism of action/substrate speci-
ficity14. Due to large molecular weight, aptamers avoid such
localised interactions or supplement them with additional interac-
tions with the surface residues. Surface residues, in turn, are not
involved in catalysis or substrate binding and, therefore, are highly
variable and characteristic for particular enzymes. Such a conclu-
sion is supported by available crystal structures. Analysis of twelve
available structures of aptamer-ligand complexes deposited in
Protein Data Bank (PDB) brings a general observation as to a
molecular mechanism of aptamer binding – all aptamers charac-
terised in this regard interact only with the well-exposed surface
residues and charged residues are preferred. A similar mechanism
is expected for T24 and T59 which most likely bind at the surface
of trypsin blocking the access of the substrate to catalytic cleft by
steric hindrance. This proposed mode of interaction would explain
why our aptamers inhibit bovine, but not porcine trypsin despite
comparable substrate specificity of these enzymes and 82%
sequence identity (note that the differences are found mostly in
surface exposed regions).
Figure 4. Dose-dependent inhibition of trypsin by aptamers: T24, T59, and T159.
Trypsin was preincubated in the presence of indicated concentrations of aptamers
before the residual activity was determined using chromogenic substrate
(L-BAPNA).
Figure 5. Aptamers selected towards bovine trypsin do not inhibit porcine
homolog. Bovine and porcine trypsin were pre-incubated with T24 and T59.
Residual proteolytic activity was determined using chromogenic substrate (L-
BAPNA) by monitoring absorbance at 405 nm.
Figure 6. Trypsin aptamer specificity. Mammalian proteases: porcine pancreatic
elastase, human cathepsin G, neutrophil elastase, plasmin, and thrombin were
pre-incubated with T24 and T59. Residual proteolytic activity was determined
using substrates relevant for each protease (see Materials and Methods).
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Analysis of Lineweaver–Burk plots and binding kinetics corrob-
orates the hypothesis on aptamer binding. T24 and T59 inhibit
trypsin in a mixed-model mechanism. The equation relevant to
this model contains an a parameter (Supplementary methods),
which is related to the mode of inhibition. When a¼ 1 the inhibi-
tor does not alter the binding of the substrate and this situation
is very similar to non-competitive inhibition. When a is large,
inhibitor interaction prevents substrate binding and the model is
similar to that of competitive inhibition. Small a signifies enhance-
ment of substrate binding by the inhibitor (similar to uncompeti-
tive model). T59 and T24 are characterised by a of 6.6 and 6.
4 1016, respectively. This suggests that both aptamers inhibit
trypsin through the mechanism very close to competi-
tive inhibition.
A number of aptamers inhibiting the proteolytic activity of
proteases have been reported (Supplementary Table 1). These
molecules wary from 71 to 169 nucleotides and inhibit target
proteases with Ki ranging from 2.1 nM to 2.5mM. The Kis of T24
and T59 (176 and 475 nM, respectively) are not differs in this
regard. Interestingly, early all proteases targeting aptamers are
characterised by RNA scaffold. The only reported DNA based
inhibitor of protein C reached only 30% reduction of maximal
enzyme activity15. RNA is considered better suited for designing
of inhibitors because of the presence of a 20-OH group and
non-Watson-Crick base pairing allowing more diverse and com-
plex three-dimensional (3D) structures of RNA oligonucleoti-
des16,17. However, DNA is more stable than RNA and our study
provides an important “proof-of-concept” that potent and
highly specific protease inhibitors can be created using
DNA scaffold.
In conclusion, we successfully created ssDNA aptamers tar-
geted at bovine trypsin which inhibit the enzyme with nano-molar
affinity and high selectivity. High selectivity is especially interest-
ing considering the difficulty of achieving selectivity when target-
ing protease active sites leading to the toxic effects by the
majority of known small molecular weight inhibitors. Our results
demonstrate that SELEX is a suitable method for identification of
highly selective and potent inhibitors of human proteases and
offer the promise of providing a novel generation of therapeutic
entities with a variety of applications.
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